First interactions with EMA – Q&A 5
How should we approach pricing and reimbursement across EU countries?
What's Inside the Q&A:
Country-Specific Value Strategies
– Why a one-size-fits-all approach fails in Europe. How to tailor messaging to each market’s unique assessment criteria.
Strategic Launch Sequencing
– How reference pricing spillover effects impact revenue. The critical importance of launch order planning to avoid pricing pitfalls.
Flexible Pricing Models
– Negotiation tactics including outcome-based agreements and risk-sharing models. How these facilitate payer acceptance for expensive therapies.
Early Market Access Planning
– When to begin crafting reimbursement strategy and essential payer engagement timelines.
